Clinical Trial Update: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating JMT101 with osimertinib versus cisplatin-pemetrexed in locally advanced or metastatic NSCLC with EGFR exon 20ins mutations; status not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JMT101
• Osimertinib (osimertinib)
• cisplatin-pemetrexed

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Local Advanced or Metastatic NSCLC | Phase 3 | Status: NOT_YET_RECRUITING